



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/517,422

02/28/2005

Tomohiro Tsuji

Q85108

4344

23373 7590 10/14/2008
SUGHRUE MION, PLLC
2100 PENNSYLVANIA AVENUE, N.W.
SUITE 800
WASHINGTON, DC 20037

EXAMINER

WOOD, AMANDA P

ART UNIT

PAPER NUMBER

1657

MAIL DATE

DELIVERY MODE

10/14/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/517,422	Applicant(s) TSUJI ET AL.	
	Examiner AMANDA P. WOOD	Art Unit 1657	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 July 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3 and 6-13 is/are pending in the application.
- 4a) Of the above claim(s) 11 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 6-10, 12 and 13 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

Applicant's response filed 10 July 2008 has been received and entered.

Applicant's request for reconsideration of the finality of the rejection of the last Office action is persuasive and, therefore, the finality of that action is withdrawn.

Applicant's arguments, see pages 3-5, filed 10 July 2008, with respect to the rejection(s) of claim(s) 1-3, 6-10 and 12-13 under 35 U.S.C. 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made with respect to Nakamoto et al (US 5,693,484) in view of Sakata et al (EP 0844481) A1) and Thompson et al (US 2001/0049091 A1).

Applicant's arguments with respect to claims 1-3, 6-10, and 12-13 have been considered but are moot in view of the new ground(s) of rejection.

Claims 1-3, 6-10, and 12-13 have been examined on the merits.

New Rejections

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 6-10, and 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combination of Nakamoto et al (US 5,693,484) in view of Sakata et al (EP 0844481) A1) and further in view of Thompson et al (US 2001/0049091 A1).

A method is claimed of classifying and counting leukocytes comprising a step of staining cells obtained from a hematological sample treated with a hemolytic agent, a step of measuring two different types of scattered light and measuring fluorescence of the cells in a flow cytometer, steps of obtaining scattered light peak intensities and scattered light widths of the cells based on the measured scattered light, obtaining fluorescence intensities of cells based upon the measured fluorescence light, and steps of classifying and counting cells into groups of leukocytes and coincidence cells based upon the measured light intensities and fluorescence.

Nakamoto et al beneficially teach a method of classifying and counting cells in a blood or urine sample comprising measuring the scattered light intensity, scattered light pulse width, scattered light peak number, and fluorescence intensity. Nakamoto et al teach that the forward scattered light or side scattered light of each sample is detected by flow cytometry and then the pulse width of the signal is determined and regarded as corresponding to cell size. In addition, Nakamoto et al beneficially teach that blood cells are further divided into erythrocytes and leukocytes depending on the difference in fluorescence intensity. Nakamoto et al also teach that a fluorescent dye which binds nucleic acids in the cells as well as a buffer are used in the assay (see, for example, col. 5, lines 1-67; col. 6, lines 5-35).

Nakamoto et al do not expressly teach a method wherein a hemolytic agent is used to treat the hematological sample prior to fluorescent staining.

Sakata et al beneficially teach a method wherein a hematological sample is treated with a hemolytic agent that maintains immature leukocytes in a viable state without damage but damages other leukocytes. Sakata et al. teach that by damaging the leukocytes with hemolytic agent the cells are permeable to the fluorescent dye used to stain the cells' DNA, therefore only cells that have were damaged by the hemolytic agent will stain and the intensity of the fluorescent staining will correspond to the amount of DNA present in the cells, while the scattered light indicates cell size. Sakata et al beneficially teaches that the hemolytic agent used in the method comprises surface-active agents, including polyoxyethylene-based nonionic surfactants of the formula represented on page 3, solubilizers of the formulas on pages 3-4, and other ingredients as shown on page 7. Sakata et al further teach that the dye used to stain the permeabilized leukocytes is preferably a dye with specificity for the cell nucleus, especially for DNA, and in particular, cationic dyes are preferred, including those dyes listed on pages 4 and 5 (see, for example, the dye of formula I, page 5). Sakata et al teach a method wherein a flow cytometer is used to measure the sample containing stained leukocytes by measuring the scattered light and fluorescence of the cells. Sakata et al further teach a method wherein leukocytes are classified and counted based upon scattered light and fluorescence in combination. Sakata et al beneficially teach a method wherein at least one type of side scattered light and forward scattered (low or high angle) light are measured, and furthermore, a method wherein mature and

immature leukocytes are classified into at least three groups and two groups, respectively, using the difference in scattered light intensity and the difference in the fluorescence intensity measured in the sample. Sakata et al further teach in Figure 2 that the ratio of immature granulocytes (i.e., immature leukocytes) relative to mature leukocytes can be determined from the instant method, wherein Fig. 2A indicates that immature granulocytes make up 3.5% of the population of leukocytes in the sample, and Fig. 2B indicates that immature granulocytes make up 7.5% of the population of leukocytes in the sample, and blasts represent another 2% of cells in the sample (see, for example, Abstract, pg. 2, lines 30-57; pg. 3, lines 5-55; pg. 4, lines 1-55; and pg. 7, lines 35-57).

Nakamoto et al and Sakata et al do not expressly teach a method wherein leukocytes with an abnormal DNA amount are counted and classified using a method comprising fluorescent staining and measurement of the stained cells with a flow cytometer.

Thompson et al beneficially teach a method wherein the ploidy (i.e., measure of the amount of DNA contained in a cell) of cells is tested and compared to non-cancerous cells, wherein if the ploidy of the test cell is greater than that of a non-cancerous cell, then it indicates a probability that the test cell is more likely to be cancerous. Thompson et al beneficially teach that the test for ploidy can be performed on test cells derived from human blood, as well as other biological samples. In addition, Thompson et al beneficially teach that intercalating agents which bind to DNA to produce a fluorescent product are preferred to use, and that flow cytometry has been

used to determine ploidy using fluorescence. Thompson et al teach that to stain cells with intercalating agents, the cell membrane must be permeabilized by exposing the cell to a detergent so that the dye can interact with chromosomal DNA to produce the fluorescent product. Thompson et al beneficially teach that the cells are then placed into a cell sorter under conditions for the dye to fluoresce, wherein the signal is detected and quantified. Furthermore, Thompson et al teach that cancerous and non-cancerous cells are treated in the same way to determine typical ploidies of the cells and then a comparison is made between the fluorescent intensity of test cells with that of cancer and non-cancer cells. Thompson et al beneficially teach that cancerous cells typically have a higher fluorescence due to higher ploidy than non-cancerous cells (see, for example, pg. 4, pgh. 39-40; pg. 5, pgh. 41; pg. 8, pgh. 121-127).

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to modify the methods disclosed by Nakamoto et al based upon the beneficial teachings provided by Sakata et al, with respect to treating cells in the sample with a hemolytic agent so as to enable fluorescent staining of cells and then measuring and classifying those cells using flow cytometry, and by Thompson et al, with respect to the art-recognized method of permeabilizing cells for the purpose of staining and quantifying the cell's DNA so as to differentiate between cells with normal amounts of DNA and those with abnormal amounts of DNA, such as would be likely to occur in cancerous cells, as discussed above. Furthermore, Thompson et al particularly point out that cancerous cells tend to have higher ploidy than non-cancerous cells, and therefore have more DNA, and that staining with fluorescent stain and subsequent

measurement with flow cytometry is useful in determining the ploidy, and therefore, quantity of DNA in cells, e.g., in cells derived from blood to differentiate amongst cells to determine their ploidy. Based upon the beneficial teachings provided by Nakamoto et al, Sakata et al, and Thompson et al, it would have been both obvious and beneficial at the time the claimed invention was made to provide a method of measuring leukocytes in a sample using scattered light intensity, scattered light pulse width, scattered light peak number, and fluorescence intensity for the benefit of classifying leukocytes into groups of mature and immature leukocytes and those with an abnormal DNA amount. The result-effective adjustment of particular conventional working conditions (e.g., using particular hemolytic agents and/or particular fluorescent dyes) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole, was *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made, as evidenced by the cited references, especially in the absence of evidence to the contrary.

Conclusion

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA P. WOOD whose telephone number is (571)272-8141. The examiner can normally be reached on M-F 8:30AM -5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

APW
Examiner
Art Unit 1657

/Ralph Gitomer/
Primary Examiner, Art Unit 1657